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Abstract
Introduction Spontaneous reporting systems (SRSs) are
pivotal for signal detection, especially for rare events with
a high drug-attributable component, such as torsade de
pointes (TdP). Use of different national SRSs is rarely
attempted because of inherent difficulties, but should be
considered on the assumption that rare events are diluted in
international databases.
Objective The aim was to describe TdP-related events
associated with antipsychotics, H1-antihistamines and anti-
infectives in three national SRSs (in Italy, Germany and
France) and highlight potential signals of torsadogenicity
through a combined literature evaluation.
Methods A common search strategy was applied to extract
TdP-related events: (1) TdP, (2) QT interval abnormalities,
(3) ventricular fibrillation/tachycardia, and (4) sudden car-
diac death. Signals of disproportionate reporting (SDRs)
were calculated for TdP ? QT interval abnormalities and
defined by a lower limit of the 95 % confidence interval of
the reporting odds ratio (ROR)[1. Among SDRs with at
least three cases without concomitant pro-arrhythmic drugs,
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Key points
Diversity across and within national spontaneous
reporting systems is likely to be multifactorial but
informative of the local reporting pattern of drug-
induced arrhythmia.
Five potential signals, undetected by recent studies in
the FDA Adverse Event Reporting System, warrant
validation through additional post-marketing
sources, namely analytical pharmaco-
epidemiological approaches.
In the era of large international spontaneous
reporting systems, we provide preliminary evidence
on the role of national databases in detecting rare
adverse drug reactions, at least for drugs with well-
established use.
Drug Saf (2016) 39:59–68
DOI 10.1007/s40264-015-0353-1
we defined potential new signal of torsadogenicity as drugs
with no published evidence from (a) the crediblemeds
website (http://www.crediblemeds.com, as ofNovember 1st,
2014); (b) studies on the FDA Adverse Event Reporting
System (FAERS); and (c) safety trials or pharmaco-epi-
demiological studies (as of December 16th, 2014).
Results Overall, 3505 cases were retrieved (1372, 1468,
and 801 for France, Germany and Italy, respectively).
Antipsychotics were mainly recorded in Germany (792
cases), whereas antibiotics peaked at 515 and 491 (France
and Italy, respectively). Forty-one drugs met criteria for
SDRs in at least one single source, of which 31 were
detected only from one single SRS: 18, ten and three
(French, German and Italian SRS, respectively). By con-
trast, only five SDRs were detected in all national data
sources (amisulpride, aripiprazole, haloperidol, olanzapine,
risperidone). Overall, five potential new signals of tor-
sadogenicity were identified: flupentixol, ganciclovir,
levocetirizine, oxatomide and tiapride.
Conclusions We found differences across and within
national SRSs in the reporting of drug-induced TdP, which
finally resulted in five potential new signals of torsado-
genicity. These findings warrant targeted pharmacovigi-
lance studies to formally assess the existence of actual
drug–event associations.
1 Introduction
Torsade de pointes (TdP) is a rare but potentially fatal
arrhythmia characterized by a marked drug-at-
tributable component; its suboptimal prediction and
detection in pre-marketing phases of drug development
caused a number of regulatory interventions worldwide,
including drug withdrawals, restrictions and warnings, thus
making spontaneous reporting systems (SRSs) pivotal in
signal detection. The post-marketing epidemic caused by
non-cardiac drugs with TdP liability has triggered a global
response from drug regulators, drug developers and aca-
demia, which resulted in the stabilization of the reporting
rate of TdP [1].
Within the ARITMO project (http://www.aritmo-project.
org), both international andnational SRSshavebeen exploited
to comprehensively collect and analyze the torsadogenic lia-
bility of antipsychotics, H1-antihistamines and anti-infectives
for systemic use, with the ultimate goal of capturing potential
signals of torsadogenicity requiring population-based studies
and possible regulatory consideration.
National databases have been used very rarely to ana-
lyze the risk of drug-induced TdP in the post-marketing
setting [2]; this may depend on the fact that a single
national SRS is perceived to be insufficient to detect rare
events, especially as compared with the large catchment
area of international databases, such as the FDA Adverse
Event Reporting System (FAERS). Nonetheless, national
databases have the advantage of providing the actual local
picture of the risk (which depends on the real drug use) and
offer access to the patient’s medical history (the so-called
‘‘narratives’’), thus potentially enhancing the performance
of signal detection. In particular, multiple database analysis
can be used to compare results across databases, while
maintaining the diversity of reporting pattern within each
single source, and avoid the theoretical dilution phe-
nomenon that may occur when analyzing international
SRSs [3].
On these grounds, we analyzed three European national
SRSs (i.e., French, German and Italian databases), with the
following aims: (1) to describe the distribution of TdP-
related events associated with antipsychotics, H1-antihis-
tamines and anti-infectives among the different databases;
and (2) to identify novel signals of torsadogenicity, by
comparing published literature data, especially from
international SRSs, namely FAERS.
2 Methods
2.1 Data Sources: Accessibility and Technical Issues
A summary of national SRSs is provided below, with a
description of the key technical issues faced to harmonize
the process of data extraction. In all SRSs, drugs are cod-
ified through the Anatomical Therapeutic Chemical (ATC)
Classification System codes, whereas adverse reports use
Medical Dictionary for Regulatory Activities (MedDRA)
terms. Within each database, the in-house de-duplication
process was applied.
1. The French SRS (2000–2010), named the Base
Nationale de Pharmacovigilance (BNPV), is a com-
puterized information database for research purposes,
and includes medically validated reports from 31
regional pharmacovigilance centers; no data are col-
lected from the manufacturer. Data submitted to the
BNPV are stored in 14 different tables that are linked
to each other using the ‘‘report identification number’’.
The French Imputability Method is adopted for
causality assessment [4]. Reports related to vaccines
are collected only in the French database and, there-
fore, were identified and excluded if vaccine(s) was the
only reported agent. Likewise, reports on illicit drugs,
heavy metals intoxications, homeopathic treatments,
herbal medicines, medical devices, cosmetics, and
accidental ingestion of substances that are not strictly
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considered as medication (e.g., mouthwash) were
excluded [5].
2. The German SRS (2005–2010) collects all adverse
events associated with all licensed medicinal products
on the market in Germany; it is operated by the Federal
Institute for Drugs andMedical Devices (German name,
BfArM), which usually accepts reports from healthcare
professionals only. However, reports submitted by
pharmaceutical industries have been recorded since
2008. The database is accessible for research purposes,
provided that a formal application with a defined subset
of variables is presented to the Agency. Causality of
drug-induced adverse events is only suspected and not
validated. Data coverage starts in 1978, although full
electronic records are only available from 2005
onwards. Free-text search strategy cannot be performed.
Manual codification of drugs was specifically imple-
mented to systematically codify active substances intoV
level ATC codes.
3. The Italian SRS (1969–2010) is based on the Rete
Nazionale di Farmacovigilanza (RNF), a network involv-
ing the Italian Medicines Agency (AIFA), Italian regions,
local health units, hospitals, Institute of Research and Care
and drug industries. Regional pharmacovigilance centers
are responsible for causality assessment andquality control
of submitted data. Each case report is available to each
operator within the RNF in line with the authorization for
his/her type of account. For every data entry or data update
in the national database, the relevantMarketAuthorization
Holder is notified to avoid duplicate sending to Eudravig-
ilance. The drug manufacturer has the obligation to send
reports from the literature of serious adverse drug reaction
(ADR) occurring in Italy to theRNF, attaching the relevant
article. Reports coming from the literature have not been
considered in the analyses. Codification of adverse
reactions has been performed through MedDRA since
2005,whereas for the 1969–2004period, theWorldHealth
Organization Adverse Reaction Terminology (WHO–
ART) terminologywas used; a bridge is required to search
the database with both terminologies.
2.2 Case and Exposure Definition
A protocol was developed to extract all potential torsado-
genic events suspected to be attributed to antipsychotics
(ATC codeN05A), antihistamines (R06) and anti-infectives,
namely antibiotics (J01), antimycotics (J02), antimycobac-
terials (J04), antivirals (J05) and antiprotozoals (P01). As
previously detailed, four mutually exclusive groups of
events of interest were defined to fully capture the hetero-
geneous clinical nature of drug-induced TdP, in decreasing
order of drug-attributable risk. Subcategories were created
regarding the severity of the outcome, that is, whether the
event caused death or life-threatening events. These groups
were (1) TdP, (2A) symptomatic QT abnormalities, (2B)
asymptomatic QT interval abnormalities, (3A) ventricu-
lar/cardiac fibrillation, (3B) ventricular tachycardia/ar-
rhythmia (fatal/serious), (3C) ventricular tachycardia/
arrhythmia (non-fatal/serious), (4A) sudden cardiac
death/cardiac arrest, (4B) syncope (fatal/serious). Details on
outcome definition and relevant codification have been fully
provided elsewhere [6]. In the Italian and French databases, a
free-text search strategy was also performed by analyzing
narratives through automatic search, based on a list of
‘‘string’’ and/or items agreed among authors (see the Elec-
tronic Supplementary Material, Table S1). These potential
additional cases were finally validated for inclusion by a
clinical pharmacologist and/or pharmacologist with exper-
tise in pharmacovigilance (i.e., F.S. and S.A. for the French
database; U.M. for the Italian database).
2.3 Signal Detection Approach
First, we performed a disproportionality analysis in terms
of drug–case pairs and considering drugs recorded as
‘‘suspect’’. We calculated the reporting odds ratio (ROR)
with the relevant 95 % confidence interval (95 % CI);
signal of disproportionate reporting (SDR) was defined
when at least three cases of interest were recorded and a
statistically significant ROR emerged (i.e., lower limit of
the 95 % CI[1) [7]. Considering the high degree of drug-
attributable risk of TdP and its recognized relationship,
albeit not straightforward, with QT prolongation, we
focused disproportionality analysis on group 1 ? 2 (i.e.,
TdP ? QT interval abnormalities).
Second, we selected SDRs (group 1 ? 2) with also no
concomitant use of cardiovascular drugs, including class
I/III antiarrhythmics, or agents listed by the crediblemeds
website (http://www.crediblemeds.com, as of June 2011,
when the analysis was performed), which may act both as
confounders of the drug–event association and may also
increase the likelihood of TdP occurrence. An SDR was
defined as ‘‘substantiated’’ if at least three cases without
these concomitant agents were reported, a ‘‘qualitative’’
evaluation that takes into account the multi-hit hypothesis
in the genesis of TdP [8, 9].
Third, a combined literature evaluation was carried out
to assess the novelty of the association (i.e., unexpected-
ness). A potential signal was finally defined if a drug ful-
filled all the following criteria:
– No mention by the crediblemeds website (http://www.
crediblemeds.com, as of November 1st, 2014). All the
three lists were checked.
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– No published pharmacovigilance evidence from inter-
national SRSs The publicly available FAERS was
identified as the comparator, considering that all
pharmacological classes of interest have been covered
in the recent literature using the same search strategy
and a comparable time window [6, 8, 10–12]. Absence
of pharmacovigilance evidence was defined by nega-
tive SDRs (i.e., the ROR did not exceed the threshold
for statistical significance or less than three cases were
reported).
– No consolidated clinical evidence Published data in
humans were used, in particular those derived from
analytical pharmaco-epidemiological studies, and thor-
ough QT studies submitted for marketing approval.
Case reports were not considered (literature search as
of December 16th, 2014). Absence of clinical evidence
was defined by negative thorough QT study or clinical
study documenting only mild-to-moderate QT prolon-
gation without occurrence of arrhythmia.
3 Results
3.1 Descriptive Analysis
Overall, 3505 cases for events of interest and ARITMO
drug classes were retrieved from the three national SRSs,
with Germany ranked first (n = 1468). Large inter- and
intra-database differences were found (Table 1). The dis-
tribution of the events in France has remarkable peculiar-
ities: the largest volume of reports is related to group 3A
(i.e., ventricular fibrillation), whereas only a few cases (if
any at all) were recorded for groups 3B and 3C.
Conversely, group 3C records the largest number of reports
extracted in both the German and Italian SRSs. The con-
tribution of narratives is appreciable, especially for group
1 ? 2, both in Italy (23 %) and France (15 %).
Overall, France ranked first (n = 143) in terms of drugs
with at least one case of interest across outcomes, followed
by Italy (n = 130) and Germany (n = 110). Antibacterials
(J01) were more frequently recorded in groups 3 ? 4, and
represented 61 % (491 out of 801) in the Italian SRS and
38 % (515 out of 1372) in the German SRS. Conversely,
cases related to antipsychotics mostly emerged in the
German SRS (where they ranked first, both for groups
1 ? 2 and 3 ? 4), and were recorded in 54 % of total cases
(792 out of 1468). Antihistamines are also widely reported,
especially in German and French SRSs (Table 2). The
complete list of drugs with all data separated for each
single outcome is provided as electronic supplementary
material (see supplementary appendices S2, S3 and S4 for
France, Germany and Italy, respectively).
3.2 Signal Detection
Forty-four drugs received at least three cases in at least one
national SRS (Table 3), 41 of which met criteria for SDRs
in at least one single source. Among these, 31 SDRs were
detected only from one single national database: 18, ten
and three from the French, German and Italian SRSs,
respectively. Only five SDRs were detected in all national
data sources (amisulpride, aripiprazole, haloperidol, olan-
zapine, risperidone).
Nine SDRs detected from national SRSs were charac-
terized by at least three cases without concomitant pro-
arrhythmic drugs (signal substantiation): quinine, tiapride
Table 1 Number of
torsadogenic events for
ARITMO drug classes
(antihistamines, antipsychotics
and anti-infectives) in national
SRSs
Event National database
Francea Germany Italya
Group 1—TdP 85 (1) 44 19 (5)
Group 2A—QT abnormal fatal/serious 45 (18) 8 13 (4)
Group 2B–QT abnormal 148 (24) 202 38 (7)
Group 1 ? 2 278 254 70
Group 3A—VF 469 (7) 21 21 (7)
Group 3B—VT-VA fatal/serious 0 4 50 (12)
Group 3C—VT-VA non-fatal/serious 5 (5) 1040 441 (25)
Group 4A—SCD-CA 326 (20) 146 138 (20)
Group 4B—syncope fatal/serious 294 (0) 3 81 (26)
Group 3 ? 4 1094 1214 731
Total 1372 1468 801
SCD-CA sudden cardiac death-cardiac arrest, SRS spontaneous reporting system, TdP torsade de pointes,
VA ventricular arrhythmia, VF ventricular fibrillation, VT ventricular tachycardia
a In parenthesis: percentage of cases retrieved only through free-text search strategy in the narratives (see
Sect. 2.2 for details)
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(France), flupentixol, ganciclovir, levocetirizine, melper-
one, pipamperone (Germany), oxatomide (Italy), and rox-
ithromycin (France and Germany). A detailed signal
assessment is provided in Table 4. The combined literature
evaluation showed that three agents (i.e., pipamperone,
quinine and roxithromycin) were already listed by credi-
blemeds website, whereas melperone was the only drug
with published clinical evidence (see Sect. 4). All agents
were not captured by disproportionality analyses conducted
in FAERS by previous recent studies. Therefore, based on
pre-specified criteria, five possible new signals of tor-
sadogenicity were identified: flupentixol, ganciclovir,
levocetirizine, oxatomide and tiapride.
4 Discussion
Our study aimed at testing heterogeneity among national
SRSs and verifying whether this feature actually translates
into improvement of signal detection performance. To our
knowledge, this is the first study comparing three national
SRSs for signal detection of drug-induced TdP. Diversity
across and within national SRSs emerged in terms of dis-
tribution of TdP-related events and associated drugs; sur-
prisingly, nine SDRs captured by national SRSs were not
detected by the most recent studies on spontaneous
reporting carried out in FAERS.
Our initial hypothesis, indeed, was that spontaneous
reports in national SRSs (and submitted to FAERS) may be
diluted in FAERS, and cannot be fully appreciated in
international SRSs, thus, potentially compromising signal
detection performance. This hypothesized dilution phe-
nomenon may be theoretically ascribable to two major
issues: (1) only serious reports from European countries are
submitted to FAERS; (2) the background for comparison
may be influenced by a number of biases, including
masking effect, which was documented in FAERS and is
hard to manage by simple unmasking protocols because of
the large size and diversity of the database, characterized
by complex interdependencies between drugs and events
[13]. Actually, it is interesting to observe that the number
of cases obtained from a single national SRS largely
exceeded those retrieved from studies performed on the
entire FAERS (with the exception of levocetirizine).
Therefore, the most plausible interpretation is that only a
minority of European reports recorded in national data-
bases are submitted to FAERS. In other words, only partial,
but unmeasured, overlap is likely to exist between national
SRSs and FAERS, an unexpected phenomenon considering
the seriousness of TdP and related clinical events.
Differences among national databases in case and drugs
distribution (e.g., ventricular fibrillation was most fre-
quently reported in France; antipsychotics accounted for
the majority of reports in Germany, whereas anti-infectives
did in Italy) are likely to be multifactorial. A driving factor
is expected to be the actual pattern of drug use at the
national level, which is further influenced by marketing
penetration, pharmaceutical pressure on a given product(s),
specific safety issues causing regulatory restrictions, num-
ber of drugs available on the market, marketing life,
reimbursement issues and prevalence of the different dis-
eases. In addition, further reasons may be the different time
windows used across databases (only the Italian SRS
strongly differed from the others and collects data since
1969), as well as peculiarities in drug selection, recording,
mapping, detection and removal of duplicates, and methods
used for causality assessment within each database. The
type of reporter could also vary among SRSs. For example,
in France, the majority of reports are submitted by hospital
physicians and then validated by hospital practitioners
specialized in pharmacovigilance. Therefore, tachycardia
not leading to a hospitalization (mainly corresponding to
the group 3C) is not usually reported. Moreover, the
diagnosis of the cardiac disorder is performed mainly in
hospital and confirmed by a specialist consultation before
notification is sent to the regional center. Finally, the free-
Table 2 Distribution of torsadogenic events in national SRSs according to the pharmacological classes of interest
Pharmacological class
(ATC code)
France Germany Italy
Tot Group
1 ? 2
Group
3 ? 4
Tot Group
1 ? 2
Group
3 ? 4
Tot Group
1 ? 2
Group
3 ? 4
Antipsychotics (N05A) 320 107 213 792 140 652 122 32 90
Antihistamines (R06) 103 19 84 116 10 106 42 10 32
Antibiotics (J01) 515 52 463 265 53 212 491 16 475
Antimycotics (J02) 53 19 34 15 7 8 26 6 20
Antimycobacterials (J04) 12 3 9 2 1 1 2 0 2
Antivirals (J05) 74 8 66 26 4 22 21 0 21
Antiprotozoals (P01) 71 27 44 11 1 10 15 2 13
ATC Anatomical Therapeutic Chemical, SRS spontaneous reporting system, Tot total
Detection of Torsadogenic Signals Through National Spontaneous Reporting Systems 63
Table 3 Drugs receiving at least three cases of TdP ? QT abnormalities in at least one national SRS
Active substance France Germany Italy
No. cases LL95 %CI No. cases LL95 %CI No. cases LL95 %CI
Acepromazine 3 1.3*
Alimemazine 8 4.1*
Amisulpride 15 11.6* 10 3.8* 3 3.7*
Amoxicillin 3 0.1
Amphotericin B 4 1.2*
Aripiprazole 4 2.1* 16 2.9* 4 8.8*
Cetirizine 3 1.6*
Chloroquine 5 1.8*
Chlorprothixene 5 1.1*
Ciprofloxacin 8 0.7 5 0.8 3 0.6
Clarithromycin 8 3.0*
Clozapine 5 1.3* 8 0.8
Cyamemazine 31 7.1*
Erythromycin 6 3.2*
Fluconazole 4 0.6 3 4.4*
Flupentixol 5 3.0*
Ganciclovir 3 11.5*
Halofantrine 10 170.0*
Haloperidol 8 2.3* 9 2.1* 3 3.4*
Itraconazole 3 3.2*
Levocetirizine 3 2.3*
Levofloxacin 8 1.3* 6 1.1*
Levomepromazine 6 3.1*
Loratadine 3 2.9*
Loxapine 8 3.1*
Melperone 6 1.8*
Moxifloxacin 21 3.1* 3 1.3*
Ofloxacin 3 0.2
Olanzapine 10 2.3* 12 1.2* 3 2.9*
Oxatomide 6 27.5*
Pimozide 3 14.6*
Pipamperone 15 4.1*
Promazine 3 14.1*
Prothipendyl 9 5.6*
Quetiapine 13 1.5* 5 7.7*
Quinine 9 18.5*
Risperidone 22 3.9* 23 1.8* 3 2.9*
Roxithromycin 5 2.0* 4 3.1*
Sulfamethoxazole and trimethoprim 5 1.3*
Telithromycin 4 1.6*
Tiapride 6 2.8*
Voriconazole 10 4.1*
Ziprasidone 17 7.8*
Zuclopenthixol 6 5.7* 4 4.5*
LL95 %CI lower limit of the 95 % confidence interval of the ROR, ROR reporting odds ratio, SRS spontaneous reporting system, TdP torsade de
pointes
* Statistically significant ROR
64 E. Raschi et al.
text search strategy through narratives was not feasible for
the German SRS. The high rate of reports retrieved through
narratives in the French SRS is due to the presence of a
detailed summary of the cases (with biological exams or
electrocardiogram (ECG) results), which is routinely done
by the pharmacovigilance experts in French regional cen-
ters. Taken together, all these aspects make each SRS a
unique entity for research and may also explain why four
out of five novel signals were identified only in one data-
base. Therefore, multiple national database analysis
appears informative when studying the arrhythmogenic
potential of drugs, in order to capture the entire spectrum of
drug-induced torsadogenicity.
Our study should be interpreted with caution, in the light
of recognized limitations affecting SRSs [14]. In particular,
we acknowledge that the lack of complete patient-related
risk factors and information on drug administration do not
allow a full causality assessment of individual reports. In
addition, although a common protocol was adopted, the
aforementioned peculiarities affecting each SRS (e.g.,
population coverage, completeness of data, duplicate
detection, drug and adverse event coding, possibility to
access patient’s medical history) did not allow final data
aggregation. Nonetheless, we believe that this issue rep-
resents an important strength of the research, which clearly
emphasized the identity and unique capabilities of national
databases when investigating the torsadogenic risk of
drugs. Moreover, we cannot assess and compare the per-
formance in signal detection among national SRSs in terms
of time to first detection of a signal and the so-called false
discovery rate [15]. The former was not the core of this
work, and it is also believed to be a minor issue as we have
analyzed drugs on the market for several years. The latter
was not a pre-specified purpose of this study, it implies the
identification of reference compounds/events a priori, and
depends on a number of factors: the type of event under
investigation [16], threshold used for signal detection [17],
the adopted algorithms, which may perform differently
among databases [18], the presence of co-prescriptions
[19], the comparator used for disproportion calculation
[20], and the nature and size of the database (e.g., national
vs. international SRSs) [3].
Table 4 Assessment of disproportionality signals with substantiation emerging from national SRSs
Signal identification:
drug (SRS where
disproportionality
emerged)
Signal
substantiation:
no. cases without
CV/crediblemeds
drugsa
Literature evaluation Characterization of
TdP signal: authors’
assessmentCrediblemeds
b
(Y/N)
PhV evidence
(Y/N with notes)
Clinical
evidence
(Y/N)
Flupentixol (Germany) 5/5 N N (only 2 cases of asymptomatic QT
prolongation in FAERS) [6]
Nc Potential new signal
Ganciclovir (Germany) 3/3 N N (only 1 case of TdP in FAERS) [8] N Potential new signal
Levocetirizine
(Germany)
1/3 N N (3 cases of asymptomatic QT
prolongation in FAERS;
LL95 %CI = 0.84) [12]
Nd Potential new signal
Melperone (Germany) 6/6 N N (no cases in FAERS) [6] Ye Signal confirmed
Oxatomide (Italy) 6/6 N N (no cases in FAERS) [12] N Potential new signal
Pipamperone
(Germany)
13/13 Y N (only 1 case of TdP in FAERS) [6] N Signal confirmed
Quinine (France) 9/1 Y N (no cases in FAERS) [8] N Signal confirmed
Roxithromycin (France;
Germany)
2/3 (France); 3/4
(Germany)
Y N (only 1 case in FAERS) [10] N Signal confirmed
Tiapride (France) 3/3 N N (only 1 case of TdP in FAERS) [6] N Potential new signal
The term ‘‘signal confirmed’’ indicates that the statistically significant association was already identified by at least one of the sources for
literature evaluation. In bold, ‘‘potential new signal’’ indicates a statistically significant association, with previously undocumented literature data
CV cardiovascular (see Sect. 3 for details), FAERS Food and Drug Administration Adverse Event Reporting System, LL95 %CI lower limit of
the 95 % confidence interval of the reporting odds ratio, PhV pharmacovigilance, SRS spontaneous reporting system, TdP torsade de pointes
a http://www.crediblemeds.org, as of June 2011, which reflects the analyses on SRSs
b http://www.crediblemeds.org, as of November 1st, 2014, which reflects the literature evaluation
c Clinical study with QT prolongation [33]
d Negative thorough QT study [27]
e Epidemiological study in Germany with spontaneous reports of TdP [24]
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We are aware that, theoretically, the five potential new
signals may be false positives, especially considering the
aforementioned methodological issues (common to all
analyses on SRSs). In addition, there are three specific
aspects to be mentioned. (1) The automatic multi-step data
mining approach performed in FAERS, especially drug
codification, de-duplication process and handling of missing
data, may affect signal detection. There is the possibility that
reports coming from national European SRSs were entered
into FAERS without filling all key information (e.g., age,
sex) and were therefore removed from published FAERS
analyses [21]. (2) FAERS is not the only international SRS
for comparison: Vigibase and Eudravigilance represent large
international databases, but did not fulfill our criteria (i.e.,
published literature evidence) for signal detection when the
study was planned. However, as previously demonstrated,
FAERS reports on TdP were mostly submitted by US and
European high-income/upper middle-income countries, thus,
supporting the notion that FAERS data are highly informa-
tive of the global pattern of torsadogenic events [11]. Future
studies should consider the use of other international sour-
ces, especially in the light of the current role of Eudravigi-
lance, which recently started data collection also on
medicinal products not approved through the centralized
procedure. (3) Additional cases were extracted through free-
text search. Nonetheless, we strongly believe that this was
unlikely to result in false positives. The analysis of narra-
tives represents an actual added value of our study because
the manual validation of cases increases the sensitivity of the
search without affecting the overall performance (manual
codification of narratives is performed for all events recor-
ded in the Italian database, thus, no major distortions are
likely to occur). Although the contribution of narratives
appears minor as compared with the standard approach
(approximately 6 % in France and 10 % in Italy), the fact
that few reports originated from free-text analysis strongly
indicates the good quality of the overall codification process,
which, both in Italy and France, involves a number of
regional centers. Despite these limitations, we believe that
the false-positive rate is likely to be low, as demonstrated by
known associations detected by our analysis (i.e., drugs
listed by crediblemeds such as haloperidol), which can be
considered as positive controls and support the accuracy of
the method.
Our study carries important clinical, research and reg-
ulatory implications. From a clinical standpoint, antipsy-
chotics are the most frequently reported agents, especially
in Germany. Notably, amisulpride, aripiprazole, haloperi-
dol, olanzapine and risperidone were the only drugs asso-
ciated with SDRs in all databases. This consistency across
all SRSs is indicative of a known pro-arrhythmic risk and
may be also related to the considerable and increasing
population exposure over years [11].
From a research standpoint, multiple database analyses
are only rarely exploited for signal detection: we believe that
the use of different SRSs represents an added value in the
current era of drug safety research, where several consortia
have been created to fully assess drug-related risks in the
post-marketing setting. As compared with post-marketing
safety studies on healthcare databases, where multiple
databases are pooled to increase statistical power, sponta-
neous reporting databases should not be combined, but
analyzed separately to maintain country-specific differ-
ences. Further research is now warranted to test the overall
signal detection performance of national SRSs when study-
ing rare events with newly approved drugs (especially in
terms of time to first detection), for which data aggregation is
theoretically advisable considering the centralized approval
of the majority of current medicinal products.
From a regulatory standpoint, the remarkable proportion
of torsadogenic reports recorded for antipsychotics in
Germany deserves consideration by national authorities
and may partially reflect their widespread prescriptions in
nursing home residents with dementia, especially for first-
generation agents with sedative properties [22, 23]. The
SDR found for melperone is consistent with results from
the recent prospective surveillance study in Berlin, which
highlighted melperone as one of the drugs most frequently
associated with TdP reports in Germany; this study further
suggested a considerably higher incidence of TdP in Ger-
many as compared with previous estimates (2.5–4 per
million per year) [24].
Literature data of flupentixol and ganciclovir are scant
and mainly based on a few case reports suggesting that
underlying comorbidities and/or clinical conditions for
which the drug is prescribed (encephalitis, immunocom-
promised patients) enhance patients’ susceptibility to TdP
occurrence [25, 26].
The signal of levocetirizine emphasized that (a) the
predictive value of thorough QT study is suboptimal [27]
and (b) enantiomers and racemic mixtures may have dif-
ferent safety profiles because of possible differences in
doses, metabolism and stereoselective targets [28]. It is
worth noting that the signal arose from the German SRS,
although no recent drug utilization data are publicly
available. A previous European cross-national comparison
study on aggregated data (2000–2005 period) reported an
unexpected low use of reimbursed antihistamines, which
was interpreted in the light of legislation on over-the-
counter products [29]. The latest European drug utilization
analysis found that levocetirizine was largely used in
France, where the drug represented 53 % of the total
defined daily doses of antihistamines [12].
As regards oxatomide, the Italian regulatory agency in
2010 required an update of the summary of product char-
acteristics, with details for posology optimization and a
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contraindication in children aged \1 year, following
potential administration errors of oral drops with risk of
overdosage [30]. The case of oxatomide represents an
example of how a signal detected by a national agency
using a standard signal detection algorithm was managed at
a local level. Therefore, we do not foresee the need for
further regulatory actions or analytical pharmaco-epi-
demiological studies.
As regards tiapride, a literature review failed to identify
consolidated clinical evidence; only a single case report is
documented in an elderly patient with agitation and con-
comitant heart disease and bronchitis [31], with reassuring
in vitro data: the inhibitory effect on potassium current was
well above the reported therapeutic plasma concentrations
achieved in humans [32].
5 Conclusions
We highlighted diversity within and across three national
SRSs, which resulted in five potential signals undetected in
FAERS. Considering that false-positive signals are possible,
these findings warrant further investigations through (a) tar-
geted analytical safety studies to formally assess these
safety signals and (b) additional analysis of other interna-
tional SRSs to assess the degree of overlap across databases,
and finally confirm the actual value of national SRSs in
signal detection.
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